This approach is consistent with current diagnostic guidelines for LAM, which recognize serum VEGF-D as a diagnostic biomarker and acknowledge that biopsy may not always be necessary when clinical and radiological findings are characteristic. The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.